Clinical Research/The Lancet/6h ago
177Lu-PSMA-617 Combined with ADT and ARPI Shows Promise in Advanced Prostate Cancer Treatment
A recent phase 3 randomized controlled trial has demonstrated that the combination of 177Lu-PSMA-617 with androgen deprivation therapy (ADT) and androgen receptor pathway inhibitors (ARPI) significantly prolongs radiographic progression-free survival in patients with PSMA-positive metastatic androgen pathway modulator-naive/sensitive (APMN/S) prostate cancer. This finding is crucial as it suggests a potential new treatment strategy for a patient population that currently has limited options. While the combination therapy did result in a higher frequency of adverse events, the safety profile remained consistent with expectations, indicating no unexpected safety concerns. As the medical community continues to seek effective therapies for advanced prostate cancer, this combination could represent a significant advancement in treatment protocols. Future studies will be necessary to further evaluate the long-term efficacy and safety of this regimen.
prostate cancer / clinical trial / 177Lu-PSMA-617 / ADT / ARPI
Health Tech
Leadership Changes at Tufts Medicine Amid Financial Turnaround Efforts
Tufts Medicine is undergoing significant leadership changes as it grapples with financial difficulties. CEO Mike Dandorph will step down at the end of September after more than six years in the role, with Phil Okala, the current chief operating officer, set to take over. Additionally, Chief Financial Officer Andrew Devoe is resigning after two years, with Greg Kruse stepping in to manage budget planning and financial services during the search for a new CFO. Dandorph's tenure has been marked by challenges, particularly during the COVID-19 pandemic, but he has been credited with enhancing access to care and advancing research initiatives. The health system, which operates four hospitals in eastern Massachusetts, has faced ongoing financial struggles exacerbated by worker shortages and a decline in revenue post-pandemic. In recent years, Tufts has made significant workforce reductions, including layoffs of 174 employees in 2024 and 70 administrative staff in 2023, alongside the sale of its laboratory outreach testing business to Labcorp, resulting in the loss of 600 jobs. Despite these challenges, Tufts Medicine has shown signs of improvement, reporting a net loss of $51.6 million for the 2025 fiscal year, a notable recovery from a $214 million loss the previous year. The leadership transition is seen as a strategic move to strengthen the organization’s financial position and continue its mission of serving patients and communities effectively. As Okala prepares to assume his new role, he emphasizes a commitment to enhancing the health system's operational focus and discipline as it enters the next phase of its financial recovery.
Healthcare Dive · 10h agoHinge Health Acquires Cylinder Health for $105M, Expanding into Gastrointestinal Care
Healthcare Dive · 15h agoFDA Approves Moderna's Innovative mRNA Flu Vaccine for Adults 50 and Older
Healthcare Dive · 17h agoDisease & Epidemiology
FDA Grants Accelerated Approval for Replimune's Melanoma Treatment After Previous Rejections
The FDA has granted accelerated approval for Replimune's RP1, now branded as Tudriqev, for the treatment of advanced melanoma. This decision marks a significant turnaround for the biotech company, which faced two prior rejections. The approval follows a recent advisory committee vote that supported the treatment, despite concerns raised by FDA staff regarding the trial's design and execution. The urgency for new therapies in melanoma, a condition with limited treatment options, played a crucial role in the decision-making process. Tudriqev will be priced at $450,000 per treatment course, excluding potential rebates and discounts. This high cost reflects the ongoing trend of escalating drug prices in oncology, raising questions about accessibility for patients. The approval is expected to impact a significant number of patients diagnosed with advanced melanoma, who are in need of effective treatment alternatives. Moving forward, Replimune will need to continue monitoring the drug's performance in real-world settings and may face additional scrutiny regarding its long-term efficacy and safety. The approval of Tudriqev could pave the way for further innovations in melanoma treatment and influence future regulatory decisions for similar therapies.
STAT News · 8h agoMedicare's Policy Change Delays Price Negotiations for AbbVie Drug, Advocacy Group Claims
A recent analysis by the consumer advocacy group Public Citizen has revealed that a policy shift by Medicare has resulted in a seven-year delay for price negotiations on a high-cost drug from AbbVie. This decision, which has gone largely unnoticed, is expected to have significant financial implications for taxpayers. The delay comes as the Centers for Medicare and Medicaid Services (CMS) prepares for a new round of negotiations with pharmaceutical companies regarding the prices they will pay for select medications. This negotiation process was established under the Inflation Reduction Act, enacted in 2022, aimed at addressing the escalating costs of prescription drugs. The implications of this policy change are critical, as it may hinder efforts to control drug prices and ensure affordability for Medicare beneficiaries. As the situation develops, stakeholders in the healthcare sector will be closely monitoring the outcomes of these negotiations and their impact on drug pricing strategies moving forward.
STAT News · 9h agoNew Insights into Tau Protein's Role in Neurodegeneration Could Inform Alzheimer's Drug Development
Recent research led by Stanford scientists has unveiled a novel function of the tau protein, a key target in Alzheimer's drug development. The study highlights tau's involvement in disrupting mitochondrial function by causing reverse electron transport, which leads to the production of reactive oxygen species and subsequent cellular stress and inflammation. This discovery is significant as it opens new avenues for therapeutic interventions aimed at mitigating neurodegeneration associated with Alzheimer's and similar neurological disorders. The researchers demonstrated that inhibiting this reverse electron transport not only alleviated the detrimental effects on cellular health but also enhanced cognitive functions, as evidenced by improved learning and memory in model organisms such as flies and mice. While the direct applicability of these findings to human patients remains to be established, preliminary analyses of human cell cultures and brain tissues indicate that targeting this mechanism could promote neuronal health. In light of these promising results, two authors of the study have initiated a biotech startup focused on further exploring this therapeutic strategy. The implications of this research could be profound, potentially leading to innovative treatments that address the underlying mechanisms of Alzheimer's disease and improve patient outcomes. As the field of neurodegenerative disease research continues to evolve, this study represents a critical step forward in understanding and combating Alzheimer's disease.
STAT News · 13h agoPharma & Medications
FDA Approves Replimune's Melanoma Treatment Tudriqev After Previous Rejections
On August 6, 2026, the FDA granted approval for Replimune's melanoma treatment, Tudriqev, following two prior rejections. This decision was influenced by an advisory panel that supported the treatment despite concerns raised by FDA reviewers regarding the trial design and response measurement. Tudriqev, previously known as RP1, is an engineered oncolytic virus administered directly into tumors, working in conjunction with Bristol Myers Squibb's Opdivo for patients whose melanoma has progressed after immunotherapy treatments like Opdivo and Merck's Keytruda. The approval is classified as 'accelerated,' meaning its continued availability will depend on the outcomes of an ongoing Phase 3 trial comparing the Tudriqev-Opdivo combination against PD-1 inhibitors or chemotherapy, with results expected in late 2027. Initial trial data indicated that approximately 25% of participants experienced some level of tumor response, lasting a median of over 14 months. The urgency for effective treatments in advanced melanoma is underscored by the often dire prognosis for patients who have exhausted existing options. Replimune's approval is a significant milestone for the company, which faced the possibility of halting development if the drug was rejected again. Analysts predict that Tudriqev could generate substantial revenue, with estimates ranging from $618 million to $1 billion in peak annual sales. The approval process for Tudriqev has been tumultuous, reflecting broader challenges within the FDA's regulatory environment, particularly under previous leadership. The recent advisory panel's support and the potential for a confirmatory trial to provide further evidence of efficacy have bolstered confidence in the treatment's future.
BioPharma Dive · 7h agoClinical Research
177Lu-PSMA-617 Combined with ADT and ARPI Shows Promise in Advanced Prostate Cancer Treatment
A recent phase 3 randomized controlled trial has demonstrated that the combination of 177Lu-PSMA-617 with androgen deprivation therapy (ADT) and androgen receptor pathway inhibitors (ARPI) significantly prolongs radiographic progression-free survival in patients with PSMA-positive metastatic androgen pathway modulator-naive/sensitive (APMN/S) prostate cancer. This finding is crucial as it suggests a potential new treatment strategy for a patient population that currently has limited options. While the combination therapy did result in a higher frequency of adverse events, the safety profile remained consistent with expectations, indicating no unexpected safety concerns. As the medical community continues to seek effective therapies for advanced prostate cancer, this combination could represent a significant advancement in treatment protocols. Future studies will be necessary to further evaluate the long-term efficacy and safety of this regimen.
The Lancet · 6h ago177Lu-PSMA-617: Advancements in Treating Metastatic Androgen Pathway Modulator-Sensitive Prostate Cancer
The Lancet · 6h agoPhase 1 Trial of B7-H3-Targeting CAR-T Cells Shows Promise for Recurrent Glioblastoma
Nature Medicine · 1d agoPsilocybin Shows Promise in Treating Treatment-Resistant Depression in NHS Trial
Nature Medicine · 1d agoHealth Policy
KFF Health News Minute Highlights Financial Well-Being and AI in Healthcare
In the latest KFF Health News Minute, experts in suicide prevention emphasize the critical link between financial stability and mental health, suggesting that enhancing Americans' financial well-being could significantly reduce suicide rates. This perspective underscores the importance of addressing economic factors as part of comprehensive mental health strategies. Additionally, the Trump administration has proposed easing regulations on artificial intelligence in healthcare, aiming to accelerate innovation in the sector. This move has sparked discussions about the balance between fostering technological advancement and ensuring patient safety. The KFF Health News Minute is released weekly, providing timely updates on pressing health issues and policy changes that affect the healthcare landscape.
KFF Health News · 19h agoNew Medicaid Work Requirements Threaten Coverage for Homeless Individuals
The recent implementation of Medicaid work requirements poses significant challenges for vulnerable populations, particularly the homeless. Under new federal regulations, individuals receiving Medicaid must demonstrate employment, volunteering, or educational engagement to maintain their benefits. This change, effective January 2024, has already been adopted by states like Montana, Arkansas, and Nebraska. The regulations exempt certain groups, including those with disabilities and individuals over 64, but do not recognize homelessness as a qualifying condition for exemption. This oversight has raised concerns among advocates and healthcare professionals about the potential impact on individuals like Tywon Pugh, who struggles with seizures and homelessness after the death of his wife. Data from the Department of Housing and Urban Development indicates a 27% increase in homelessness in the U.S. from 2013 to 2025, with approximately 746,000 individuals experiencing homelessness last year. Many of these individuals qualify for Medicaid, yet the number of enrollees who are homeless remains difficult to quantify. In 2023, 55% of patients receiving services through Health Care for the Homeless programs were enrolled in Medicaid, highlighting the program's critical role in providing healthcare access to this population. The new regulations are expected to increase the uninsured rate by over 5 million by 2034, according to the Congressional Budget Office. States like Montana are preparing to enforce these requirements as early as October 2023, raising fears among beneficiaries about losing essential healthcare coverage. Advocates argue that the stringent criteria for exemptions will disproportionately affect those unable to meet work requirements due to their circumstances, such as homelessness or medical conditions. As states navigate these changes, the implications for healthcare access and outcomes for vulnerable populations remain a pressing concern.
KFF Health News · 19h agoSenator Andy Kim Proposes Universal Health Coverage for All Children in the U.S.
In a recent interview, Senator Andy Kim, a Democrat from New Jersey, outlined his proposal to ensure that all children in the United States have access to health coverage. Kim, who is a member of the Senate Health, Education, Labor and Pensions Committee, emphasized the importance of providing every child with the ability to see a doctor without financial barriers. His plan, referred to as 'MediKids,' would automatically enroll children in a public health program at birth, allowing parents the option to opt out but enabling re-enrollment until the age of 26. Kim argues that universal health coverage for children is not only a moral obligation but also a strategic investment in the nation's future. By ensuring that children receive necessary medical care during critical developmental years, the proposal aims to prevent chronic health issues in adulthood and contribute to a healthier workforce overall. The senator believes that this initiative could gain momentum if Democrats secure a majority in Congress during the upcoming midterm elections and could also play a significant role in shaping healthcare discussions leading up to the 2028 presidential race. The proposal highlights a growing recognition of the need for comprehensive healthcare solutions in the U.S., particularly for vulnerable populations such as children. As healthcare continues to be a pivotal issue in American politics, Kim's initiative could spark further dialogue on how to improve access and affordability in the healthcare system. The discussion around 'MediKids' is part of a broader conversation about healthcare reform, including the resurgence of ideas like 'Medicare for All.'
KFF Health News · 19h agoNutrition & Prevention
CDC Issues Food Safety Alert for Salmonella Outbreak Linked to Jalapeños
The Centers for Disease Control and Prevention (CDC) has issued a food safety alert regarding a multistate outbreak of Salmonella infections associated with the consumption of jalapeños. This warning comes as health officials investigate the source of the outbreak, which has affected numerous individuals across several states. Salmonella is a significant public health concern, as it can lead to severe gastrointestinal illness and, in some cases, hospitalization. The CDC is urging consumers to avoid eating jalapeños until further notice and is working closely with local health departments to track the spread of the infection. As the investigation continues, healthcare professionals are advised to remain vigilant for symptoms of Salmonella infection in patients who may have consumed these peppers recently.
CDC Healthy Living · 1d ago